The Oncology Institute, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +35.4%
EBITDA: +41.1%
EBIT: +37.2%
EPS: +50.0%
Free cash flow: -34.3%
Operating cash flow: -39.4%

Forward estimates

Revenue: -36.2%
EBITDA: -100.0%
EPS: +65.7%

Three-year CAGR

Revenue: +25.8%
EBITDA: +16.4%
EBIT: +40.0%
Net income: +6.3%
EPS: +23.9%
Free cash flow: +8.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.